[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 70 pages | ID: MDBABC528BD4EN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Middle East Respiratory Syndrome (MERS) Drug pipeline report- 2020 is an annual R&D review of Middle East Respiratory Syndrome (MERS) pipeline candidates. The report presents the current status of all major Middle East Respiratory Syndrome (MERS) therapeutic compounds. Detailed insights into Middle East Respiratory Syndrome (MERS) pipeline development, current status, companies, drug profiles and Middle East Respiratory Syndrome (MERS) preclinical and clinical trials are included.

2020 Middle East Respiratory Syndrome (MERS) Pipeline Market Insights
Middle East Respiratory Syndrome (MERS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Middle East Respiratory Syndrome (MERS) therapies, pipeline by phase and others are included.

Middle East Respiratory Syndrome (MERS) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Middle East Respiratory Syndrome (MERS) Therapeutic Drug candidates
Both active and inactive Middle East Respiratory Syndrome (MERS) pipeline drug candidates are included in the report

Middle East Respiratory Syndrome (MERS) Clinical Trials and preclinical Studies
Middle East Respiratory Syndrome (MERS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Middle East Respiratory Syndrome (MERS) pipeline market developments
Middle East Respiratory Syndrome (MERS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Middle East Respiratory Syndrome (MERS) pipeline companies in active development
The report analyzes Middle East Respiratory Syndrome (MERS) pipeline of the below companies-

Autoimmune Technologies LLC, Fabentech, Gilead Sciences Inc, Global BioLife Inc Ltd, Greffex Inc, Humabs BioMed SA, Inovio Pharmaceuticals Inc, Kineta Inc, NanoViricides Inc, Novavax, Inc, Organic Vaccines PLC, Phelix Therapeutics LLC, Planet Biotechnology Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, SAB Biotherapeutics Inc, Signia Therapeutics, Themis Bioscience GmbH, Vaccitech ltd, Vaxine Pty Ltd, Vir Biotechnology Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
21 Companies investing in Middle East Respiratory Syndrome (MERS) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Middle East Respiratory Syndrome (MERS) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE MARKET INSIGHTS, 2020

1.1 Middle East Respiratory Syndrome (MERS) Disease Overview
1.2 Middle East Respiratory Syndrome (MERS) Drug Pipeline Snapshot, 2020
  1.2.1 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Phase
  1.2.2 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Company
  1.2.3 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Mechanism of Action
  1.2.4 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Route of Administration

2. MIDDLE EAST RESPIRATORY SYNDROME (MERS) COMPANY WISE PIPELINE DETAILS

Autoimmune Technologies LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Fabentech Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Gilead Sciences Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Global BioLife Inc Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Greffex Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Humabs BioMed SA Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Inovio Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Kineta Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
NanoViricides Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Novavax, Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Organic Vaccines PLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Phelix Therapeutics LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Planet Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Regeneron Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Romark Laboratories LC Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
SAB Biotherapeutics Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Signia Therapeutics Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Themis Bioscience GmbH Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vaccitech ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vaxine Pty Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vir Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. MIDDLE EAST RESPIRATORY SYNDROME (MERS) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications